Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure

Renal Failure

Volumn 32, Issue 9, 2010, Pages 1073-1080

  Teixeira, Ana Margarida ^a   Garrido, Patrícia ^a   Santos, Paulo ^b   Alves, Rui ^a   Parada, Belmiro ^a   Costa, Elísio ^c,d   Almeida, Anabela ^b   Teixeira Lemos, Edite ^a   Sereno, José ^a   Pinto, Rui ^e   Belo, Luís ^d,f   Santos Silva, Alice ^d,f   Teixeira, Frederico ^a,d   Reis, Flávio ^a,d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Center of Histocompatibility of the Centre   (Portugal)

^c CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF LISBON   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

Author keywords

apoptosis; cardio renal protection; hypertrophy; moderate chronic renal failure; proliferation; rhEPO treatment

Indexed keywords

ADRENALIN; CASPASE 9; CREATININE; DNA TOPOISOMERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; MESSENGER RNA; NORADRENALIN; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA1; UREA; URIC ACID; VASCULOTROPIN;

ADRENALIN BLOOD LEVEL; ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; GENE EXPRESSION; HEART PROTECTION; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; KIDNEY HYPERTROPHY; MALE; NEPHRECTOMY; NONHUMAN; NORADRENALIN BLOOD LEVEL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ANIMALS; BLOOD PRESSURE; CASPASE 9; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN, RECOMBINANT; HEART DISEASES; HEART RATE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; PERIPHERAL NERVOUS SYSTEM; RATS; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC; SYMPATHETIC NERVOUS SYSTEM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957274297     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.509897     Document Type: Article

References (28)

1. Deicher R, Hörl WH. Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2003;12:139-143. (Pubitemid 36288313)
2. Stevens LA, Levin A. Anaemia, cardiovascular disease and kidney disease: Integrating new knowledge in 2002. Curr Opin Nephrol Hypertens. 2003;12:133-138. (Pubitemid 36288312)
3. Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents - What do we know and what needs to be clarified? Nephrol Dial Transplant. 2005;20:2-7.
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anaemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61. (Pubitemid 26231466)
5. Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13: 1642-1644. (Pubitemid 28306788)
6. Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A. The cardio-renal anaemia syndrome: Does it exist? Nephrol Dial Transplant. 2003;18:7-12. (Pubitemid 37509094)
7. Palazzuoli A, Gallotta M, Iovine F, Nuti R, Silverberg DS. Anaemia in heart failure: A common interaction with renal insufficiency called the cardio-renal anaemia syndrome. Int J Clin Pract. 2008;62:281-286.
8. Fluck R. Controversies in chronic kidney disease, anaemia and cardiovascular disease. Br J Hosp Med. 2008;69:580-586.
9. McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest. 2005;35:58-65. (Pubitemid 41783606)
10. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-95. (Pubitemid 40066704)
11. Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev. 2008;13:415-423.
12. Bogoyevitch MA. An update on the cardiac effects of erythopoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res. 2004;63:208-216.
13. Manolis AS, Tzeis S, Triantafyllou K, et al. Erythropoietin in heart failure and other cardiovascular diseases: Hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:355-375. (Pubitemid 41631546)
14. Shang Y, Wu Y, Yao S, Wang X, Feng D, Yang W. Protective effect of erythropoietin against ketamine-induced apoptosis in cultured rat cortical neurons: Involvement of PI3K/Akt and GSK-3 beta pathway. Apoptosis. 2007;12:2187-2195. (Pubitemid 350077253)
15. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17:1754-1755.
16. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock. 2004;22:63-69. (Pubitemid 40228212)
17. Ma R, Xiong N, Huang C, et al. Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signalling pathway. Neuropharmacology. 2009;56: 1027-1034.
18. Garrido P, Reis F, Costa E, et al. Characterization of a rat model of moderate chronic renal failure - Focus on hematological, biochemical and cardio-renal profiles. Ren Fail. 2009; 31:833-842.
19. Reis F, Rocha L, Ponte L, et al. Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sci. 2005;77:2514-2528. (Pubitemid 41222325)
20. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:R34.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-CT method. Methods. 2001;25:402-408.
22. Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int. 2009;75:682-688.
23. Fernandez-Fresnedo G, Rodrigo E, De Francisco AL, De Castro SS, Castañeda O, Arias M. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients. J Am Soc Nephrol. 2006;17:S246-S249. (Pubitemid 44865256)
24. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33:821-828.
25. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59:538-548.
26. Jie KE, Verhaar MC, Cramer MJ, et al. Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol. 2006;291:F933-F944.
27. Piloto N, Teixeira HM, Teixeira-Lemos E, et al. Erythropoietin promotes deleterious cardiovascular effects and live risk in a rat model of chronic sports doping. Cardiovasc Toxicol. 2009;9:201-210.
28. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol. 2004;15:524-537.